Abiraterone Acetate Prolongs Survival in Metastatic Prostate Cancer
the Cancer Therapy Advisor take:
COU-AA-302 trial was conducted earlier in 2013 to evaluate whether abiraterone acetate, an androgen biosynthesis inhibitor, improved overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy.
The planned interim analysis from the trial showed that abiraterone acetate plus prednisone significantly improved radiographic progression-free survival compared with placebo plus prednisone. Recently, a placebo-controlled, double-blind, randomized study, presenting presepecified final analysis of the COU-AA-302 trial, was published.
The objective of the study was to assess the effect of abiraterone acetate plus prednisone on overall survival, time to opiate use, and use of other subsequent therapies.
There were 1,088 patients in the study who were asymptomatic or mildly symptomatic with chemotherapy-naïve prostate cancer. Patients were randomly assigned to receive either abiraterone acetate plus prednisone (abiraterone acetate group), or placebo plus prednisone (placebo group). Of the prespecified 773 death events for the final analysis, 65% of patients in the abiraterone acetate group experienced death events and 71% in the placebo group.
Results showed that the median overall survival was significantly longer in the abiraterone acetate group than in the placebo group (34.7 months [95% CI 32.7-36.8] versus 30.3 months [28.7-33.3]; hazard ratio 0·81 [95% CI 0.70-0.93]; p=0·0033).
Subsequent treatment with one or more approved agents was used in 67% of patients in the abiraterone acetate group and 80% in the placebo group. Among the patients in the placebo group, 44% subsequently received abiraterone acetate therapy.
Overall, the authors concluded that abiraterone acetate significantly prolonged overall survival compared to prednisone monotherapy in the treatment of chemotherapy-naive metastatic castration-resistant prostate cancer. The clinical and statistical significance supports a favorable safety profile for abiraterone acetate.
Abiraterone acetate improved overall survival in patients with metastatic castration-resistant prostate cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Plastics and Cancer
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer